On 23 May 2025, MiRXES Holding Company Limited (2629.HK, MiRXES’) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 1.09 billion. CBI is honored to participate in the due diligence work for this IPO Project.
MiRXES is a micro ribonucleic acid (miRNA) technology company headquartered in Singapore, specializing in early cancer detection and precision medicine. The comapny provides various miRNA test kit products for the early detection of cancer and other diseases.

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, shareholders, customers and suppliers. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting related company search and reputation intelligence. The due diligence project globally covered 11 countries and regions, including China, Hong Kong, Japan, Singapore, the United States and the United Kingdom.